Tempest Therapeutics to present Phase 1b/2 hepatocellular carcinoma study data on amezalpat combo on June 20, 2024.
Tempest Therapeutics, a biotech firm developing targeted cancer treatments, will present new data from a global Phase 1b/2 study of amezalpat (TPST-1120) combined with atezolizumab and bevacizumab for first-line hepatocellular carcinoma treatment. The data will be released in a premarket press release followed by a webcasted conference call on June 20, 2024. Tempest Therapeutics is a clinical-stage biotech company based in Brisbane, California.
June 18, 2024
4 Articles